CIK 0000875320 · Large accelerated filer
VERTEX PHARMACEUTICALS INC / MA
Sign in to watch- Ticker
- VRTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- MA
- Entity type
- operating
- EIN
- 043039129
- Phone
- 6173416393
- Business address
- 50 NORTHERN AVENUE, BOSTON, MA, 02210
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $6,307,135
- in 1 filing, $6.3M under 10b5-1 plans
Net −$6,307,135. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-02-27 | Kewalramani Reshma CEO & President | Sale 10b5-1 | −2,725 | $490.54 | $1.3M | 128,545 |
| 2026-02-27 | Kewalramani Reshma CEO & President | Sale 10b5-1 | −949 | $491.30 | $466K | 127,596 |
| 2026-02-27 | Kewalramani Reshma CEO & President | Sale 10b5-1 | −2,520 | $493.29 | $1.2M | 125,076 |
| 2026-02-27 | Kewalramani Reshma CEO & President | Sale 10b5-1 | −3,498 | $494.33 | $1.7M | 121,578 |
| 2026-02-27 | Kewalramani Reshma CEO & President | Sale 10b5-1 | −15,580 | $495.38 | $7.7M | 105,998 |
| 2026-02-27 | Kewalramani Reshma CEO & President | Sale 10b5-1 | −5,995 | $496.16 | $3.0M | 100,003 |
| 2026-02-27 | Kewalramani Reshma CEO & President | Sale 10b5-1 | −1,725 | $496.95 | $857K | 98,278 |
| 2026-02-27 | Bozic Carmen EVP and CMO | Sale 10b5-1 | −2,329 | $480.31 | $1.1M | 37,734 |
| 2026-02-26 | Ambrose Kristen SVP & Chief Accounting Officer | Sale 10b5-1 | −357 | $483.36 | $173K | 6,624 |
| 2026-02-25 | Tatsis Ourania EVP, Chief Reg. & Quality Off. | Sale 10b5-1 | −260 | $486.35 | $126K | 46,763 |
| 2026-02-25 | Sachdev Amit EVP Chief Patient & Ext Af Off | Sale 10b5-1 | −1,846 | $486.35 | $898K | 55,570 |
| 2026-02-25 | McKechnie Duncan EVP, Chief Commercial Officer | Sale 10b5-1 | −2,500 | $486.35 | $1.2M | 19,969 |
| 2026-02-25 | McKechnie Duncan EVP, Chief Commercial Officer | Sale 10b5-1 | −2,410 | $489.00 | $1.2M | 17,559 |
| 2026-02-25 | Bunnage Mark E. EVP, Chief Scientific Officer | Sale 10b5-1 | −620 | $486.35 | $302K | 7,284 |
| 2026-02-25 | Biller Jonathan EVP and Chief Legal Officer | Sale 10b5-1 | −945 | $486.35 | $460K | 13,659 |
| 2026-02-25 | Atkinson Edward Morrow III EVP, Chief Technical Ops. Off. | Sale 10b5-1 | −668 | $486.35 | $325K | 18,432 |
| 2026-02-25 | Ambrose Kristen SVP & Chief Accounting Officer | Sale 10b5-1 | −223 | $486.35 | $108K | 6,981 |
| 2026-02-24 | LEIDEN JEFFREY M Executive Chairman | Shares withheld for taxes | −3,547 | $485.11 | $1.7M | 34,797 |
| 2026-02-24 | WAGNER CHARLES F JR EVP, CO & FO | Shares withheld for taxes | −1,744 | $485.11 | $846K | 47,042 |
| 2026-02-24 | Tatsis Ourania EVP, Chief Reg. & Quality Off. | Shares withheld for taxes 10b5-1 | −1,627 | $485.11 | $789K | 47,023 |
Page 4 of 10 · 182 trades